{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:54:33Z","timestamp":1782431673832,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","award":["17504"],"award-info":[{"award-number":["17504"]}],"id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1002\/rth2.12614","type":"journal-article","created":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T03:39:22Z","timestamp":1637465962000},"page":"e12614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adherence to rivaroxaban for the treatment of venous thromboembolism\u2013Results from the FIRST registry"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-9375","authenticated-orcid":false,"given":"Victoria","family":"Speed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9064","authenticated-orcid":false,"given":"Vivian","family":"Auyeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-8294","authenticated-orcid":false,"given":"Jignesh P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3871-8491","authenticated-orcid":false,"given":"Lara N.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-7990","authenticated-orcid":false,"given":"Roopen","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1002\/rth2.12614_bb0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/rth2.12614_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjh.14134","article-title":"Adherence to long\u2010term anticoagulation treatment, what is known and what the future might hold","volume":"174","author":"Abdou","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1002\/rth2.12614_bb0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/jth.12086","article-title":"Non\u2010adherence to new oral anticoagulants: a reason for concern during long\u2010term anticoagulation?","volume":"11","author":"Rodriguez","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12614_bb0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.thromres.2014.05.035","article-title":"Meta\u2010analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients","volume":"134","author":"Mearns","year":"2014","journal-title":"Thromb Res"},{"issue":"10","key":"10.1002\/rth2.12614_bb0030","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1538-7836.2012.04872.x","article-title":"Risk of post\u2010thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study","volume":"10","author":"Chitsike","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1002\/rth2.12614_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1503\/cmaj.080171","article-title":"Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta\u2010analysis","volume":"179","author":"Oake","year":"2008","journal-title":"CMAJ"},{"issue":"6","key":"10.1002\/rth2.12614_bb0040","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence\u2010based clinical practice guidelines","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"11","key":"10.1002\/rth2.12614_bb0045","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1503\/cmaj.061523","article-title":"Frequency of adverse events in patients with poor anticoagulation: a meta\u2010analysis","volume":"176","author":"Oake","year":"2007","journal-title":"CMAJ"},{"issue":"5","key":"10.1002\/rth2.12614_bb0050","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1538-7836.2005.01333.x","article-title":"Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome","volume":"3","author":"Van Dongen","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12614_bb0055","series-title":"Health at a Glance: Europe 2018: State of Health in the EU Cycle","year":"2018"},{"issue":"7","key":"10.1002\/rth2.12614_bb0060","first-page":"35","article-title":"Adherence and health care costs","volume":"20","author":"Iuga","year":"2014","journal-title":"Risk Manag Healthc Policy"},{"issue":"7","key":"10.1002\/rth2.12614_bb0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1076029615601492","article-title":"Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes","volume":"22","author":"Amin","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"10.1002\/rth2.12614_bb0070","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjmed.2017.03.038","article-title":"Association between patient\u2010reported medication adherence and anticoagulation control","volume":"130","author":"Sevilla\u2010Cazes","year":"2017","journal-title":"Am J Med"},{"issue":"9","key":"10.1002\/rth2.12614_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042269","article-title":"Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta\u2010analysis","volume":"7","author":"Erkens","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1002\/rth2.12614_bb0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.167.3.229","article-title":"The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (IN\u2010RANGE) study","volume":"167","author":"Kimmel","year":"2007","journal-title":"Arch Intern Med"},{"issue":"03","key":"10.1002\/rth2.12614_bb0085","first-page":"236","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"70","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1002\/rth2.12614_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN\u2010DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"issue":"369","key":"10.1002\/rth2.12614_bb0095","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"2013","author":"Investigators","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/rth2.12614_bb0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12614_bb0105","unstructured":"World Health Organisation. Adherence to long\u2010term therapies: evidence for action. 2003. Available from; https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence:full_report.pdf?ua=1"},{"issue":"8","key":"10.1002\/rth2.12614_bb0110","first-page":"1025","article-title":"Medication adherence: process for implementation","volume":"28","author":"Mendys","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1002\/rth2.12614_bb0115","unstructured":"National Institute of Health and Care Excellence (NICE). Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Technology appraisal guidance [TA261] 2012."},{"key":"10.1002\/rth2.12614_bb0120","unstructured":"National Institute of Health and Care Excellence (NICE). Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism technology appraisal guidance [TA287] 2013."},{"issue":"11","key":"10.1002\/rth2.12614_bb0125","first-page":"1319","article-title":"Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment\u2010na\u00efve nonvalvular atrial fibrillation","volume":"22","author":"Brown","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"10.1002\/rth2.12614_bb0130","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/phar.1989","article-title":"Real\u2010world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation","volume":"37","author":"Manzoor","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/rth2.12614_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-10-120","article-title":"The Anti\u2010Clot Treatment Scale (ACTS) in clinical trials: cross\u2010cultural validation in venous thromboembolism patients","volume":"10","author":"Cano","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"10.1002\/rth2.12614_bb0140","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/PPA.S131157","article-title":"Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long\u2010course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism","volume":"25","author":"Keita","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1002\/rth2.12614_bb0145","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure for hypertension control","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens"},{"issue":"4","key":"10.1002\/rth2.12614_bb0150","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.thromres.2015.07.007","article-title":"Self\u2010reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale","volume":"136","author":"Castellucci","year":"2015","journal-title":"Thromb Res"},{"issue":"1","key":"10.1002\/rth2.12614_bb0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self\u2010reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1002\/rth2.12614_bb0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.036","article-title":"Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoagulation service","volume":"193","author":"Packard","year":"2020","journal-title":"Thromb Res"},{"issue":"2","key":"10.1002\/rth2.12614_bb0165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003074","article-title":"Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"01","key":"10.1002\/rth2.12614_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH15-04-0350","article-title":"Therapy persistence in newly diagnosed non\u2010valvular atrial fibrillation treated with warfarin or NOAC","volume":"115","author":"Martinez","year":"2016","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1002\/rth2.12614_bb0175","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.clinthera.2016.09.014","article-title":"Comparison of adherence to rivaroxaban versus apixaban among patients with atrial fibrillation","volume":"38","author":"McHorney","year":"2016","journal-title":"Clin Ther"},{"issue":"212","key":"10.1002\/rth2.12614_bb0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2016.03.051","article-title":"Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non\u2010valvular atrial fibrillation in the United States","volume":"1","author":"Coleman","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1002\/rth2.12614_bb0185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","article-title":"Variations in patients\u2019 adherence to medical recommendations: a quantitative review of 50 years of research","volume":"42","author":"DiMatteo","year":"2004","journal-title":"Med Care"},{"issue":"6","key":"10.1002\/rth2.12614_bb0190","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3999(99)00057-4","article-title":"Patients\u2019 beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness","volume":"47","author":"Horne","year":"1999","journal-title":"J Psychosom Res"},{"key":"10.1002\/rth2.12614_bb0195","first-page":"40","volume":"2005","author":"Horne","year":"2005"},{"issue":"12","key":"10.1002\/rth2.12614_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080633","article-title":"Understanding patients\u2019 adherence\u2010related beliefs about medicines prescribed for long\u2010term conditions: a meta\u2010analytic review of the necessity\u2010concerns framework","volume":"8","author":"Horne","year":"2013","journal-title":"PLoS One"},{"key":"10.1002\/rth2.12614_bb0205","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.thromres.2017.12.021","article-title":"Exploration of adherence and patient experiences with DOACs one year after switching from vitamin\u2010K antagonists\u2010insights from the switching study","volume":"162","author":"Bartoli\u2010Abdou","year":"2018","journal-title":"Thromb Res"},{"issue":"4","key":"10.1002\/rth2.12614_bb0210","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/rth2.12316","article-title":"Self\u2010reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants","volume":"4","author":"Toorop","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12614_bb0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1002\/rth2.12614_bb0220","unstructured":"NICE N. Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing [NG158]. 2020. Available from: https:\/\/www.nice.org.uk\/guidance\/ng158"},{"issue":"6","key":"10.1002\/rth2.12614_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234048","article-title":"Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism\u2013The SWAN study","volume":"15","author":"Hendriks","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1002\/rth2.12614_bb0230","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2014.11.008","article-title":"Patient\u2010reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial","volume":"135","author":"Prins","year":"2015","journal-title":"Thromb Res"},{"issue":"26","key":"10.1002\/rth2.12614_bb0235","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/rth2.12614_bb0240","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1055\/s-0038-1641679","article-title":"Patient\u2010reported treatment experience with oral rivaroxaban: results from the noninterventional XALIA study of deep\u2010vein thrombosis","volume":"2","author":"Cano","year":"2018","journal-title":"TH Open"},{"issue":"366","key":"10.1002\/rth2.12614_bb0245","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta\u2010analysis","volume":"24","author":"Khan","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/rth2.12614_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12607","article-title":"Rivaroxaban in acute venous thromboembolism: UK prescribing experience","volume":"5","author":"Speed","year":"2021","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12614","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12614","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922014765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922014765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:21:25Z","timestamp":1762863685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922014765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2475037922014765"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12614","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to rivaroxaban for the treatment of venous thromboembolism\u2013Results from the FIRST registry","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}],"article-number":"e12614"}}